The Impact of Cognitive Impairment on Robot-Based Upper-Limb Motor Assessment in Chronic Stroke.

Thirty-one participants is a small sample, and the cognitive-motor subgroups were uneven, with 15, 7, 5, and 5 participants, so the group comparisons may be unstable. The study grouped visuospatial and executive function together, so it cannot show which of those two domains mattered more. The MoCA is a screening tool, not a detailed cognitive assessment, so it may not capture the specific cognitive demands of the robot task. The two protocols used different trial lengths, and the longer protocol may have involved fatigue, loss of interest, or attention effects. Participants were only adults at least three months after stroke who could sit upright and did not have severe spasticity or more than mild pain, so the results may not apply to more impaired or painful patients. The study was an assessment study, not a treatment trial, so it does not show that changing cognition or therapy will change motor performance. The robot outcome was tracking performance, not an activity of daily living outcome, so it does not directly show transfer to dressing, phone use, meal preparation, or finances.

The publication types list non-U.S. government and NIH extramural research support. The declaration states that Michelle Johnson and Rochelle Mendonca are founders of Recupero Robotics, LLC, a University of Pennsylvania spinoff company that commercializes affordable robots developed in the University of Pennsylvania Rehabilitation Robotics Lab.

Do not treat a poor robot tracking score as proof of a pure motor deficit. The same tracking metrics were worse when visuospatial and executive scores were impaired, and the study did not test whether any intervention would improve tracking.